Twenty Four Month Extension Study of BA058-05-003
Status: | Completed |
---|---|
Conditions: | Osteoporosis, Postmenopausal Syndrome |
Therapuetic Areas: | Endocrinology, Rheumatology |
Healthy: | No |
Age Range: | Any |
Updated: | 4/14/2017 |
Start Date: | October 2012 |
End Date: | October 2016 |
An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003
The purpose of this study is to provide 24 months of standard of care data on subjects
previously enrolled in study BA058-05-003.
previously enrolled in study BA058-05-003.
Inclusion Criteria:
1. The subject was enrolled, randomized to either the BA058 (abaloparatide) or placebo
arm, and successfully completed Study BA058-05-003.
Exclusion Criteria:
1. Were withdrawn from Study BA058-05-003 for any reason.
2. Experienced a treatment-related SAE during Study BA058-05-003.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials